Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Lecanemab is the first therapy of its kind approved in the EU that could potentially slow the progression of Alzheimer’s disease. The use of lecanemab will now be considered by national payers, who will assess the treatment against further nationally determined criteria.
This comes as the Appeals board of the European Commission were unable to reach a verdict following the “no opinion” decision of the Standing Committee on Medicinal Products for Human Use and the European Commission. The matter will now be referred the European Commission for a final decision.
As we count down the remaining days until the launch of this global event in Kraków, Poland, ADI is proud to share a message from our CEO, Paola Barbarino, and highlight some of our key speakers joining us from 24-26 April 2024.
From symposiums and conferences to high-level meetings and webinars, ADI delegates around the world have taken part in dynamic global efforts to improve the lives of those living with dementia and carers throughout the month of March.
The Wicking Dementia Centre celebrates its achievement of gaining ADI Accreditation, becoming Australia's first educational provider to attain this award. This is a significant milestone in global dementia education and marks Wicking's dedication to excellence and its commitment to enhancing care standards worldwide.
ADI is pleased to welcome both Her Majesty The Queen Sofía of Spain and Her Royal Highness Princess Muna Al Hussein of Jordan to ADI’s 36th International Conference
ADI’s Director of the Americas attends the ReD-Lat Annual Meeting in Buenos Aires, Argentina with the aim to strengthen the bonds between ADI's members and researchers attending ReD-Lat; fostering collaboration and knowledge exchange to advance the field of dementia research in Latin America and the Caribbean.
As the global voice on dementia, ADI has embarked on impactful week of advocacy in Europe and beyond. Attending the WHO Executive Board meetings in Geneva, a high level meeting of health ministries at OECD, Paris, and virtually joining the HGPI in Japan. With key members of ADI staff making multiple addresses to international bodies seeking to improve and strengthen policies that relate to dementia.
AD-RIDDLE, funded by the Innovative Health Initiative, a European Union public privative partnership, brings together academics, healthcare providers, pharmaceutical companies, regulatory bodies to develop tools and resources for healthcare providers.
ADI calls for lived experience to be central to innovation in the field of dementia diagnostics, treatment and care. In her short interview with Novartis, Paola Barbarino highlights key areas which innovators must consider when developing their products and service, from inception, to testing and ultimately bringing them to market; and reminds us not to forget that simple innovative changes can lead to great impact.